Clinical program — Phase I-II clinical study
Oncorena has completed all preclinical studies and has initiated a Phase I/II clinical study to demonstrate safety and tolerability, as well as anti-tumor activity of ONC175 (orellanine) in metastatic renal cancer patients.
The clinical Phase I/II trial protocol has been developed in collaboration with Karolinska University Hospital in Stockholm, Sweden, MD Anderson Cancer Center in Houston, US and external clinical oncology advisors and a CRO (Contract Research Organization).
Oncorena first received regulatory approval by the Swedish Medical Products Agency to start the first clinical trial of ONC175 in patients with metastatic renal cancer at Centre for Clinical Cancer Studies at the Karolinska University Hospital in Stockholm, Sweden, and the first patient was treated with ONC175 in August 2023. In March 2025 FDA approved the Oncorena IND and the trial will be initiated at the MD Anderson Cancer Center during 2025. The study will subsequently be expanded to other countries in both Europe and the US.